Author： Jurk Marion Vollmer Jörg
Publisher： Adis International
ISSN： 1173-8804
Source： BioDrugs, Vol.21, Iss.6, 2007-01, pp. : 387-401
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
CpG Oligodeoxynucleotides as TLR9 Agonists: Therapeutic Applications in Cancer
By Murad Yanal M. Clay Timothy M.
BioDrugs, Vol. 23, Iss. 6, 2009-12 ,pp. :
Access to resources
Recommend
Immune Modulation as a Therapeutic Strategy for Atherosclerosis
Current Drug Therapy, Vol. 5, Iss. 4, 2010-11 ,pp. :
CpG DNA in the Prevention and Treatment of Infections
By Dalpke A. Zimmermann S. Heeg K.
BioDrugs, Vol. 16, Iss. 6, 2002-01 ,pp. :
The CpG Motif: Implications for Clinical Immunology
By Krieg A.M.
BioDrugs, Vol. 10, Iss. 5, 1998-11 ,pp. :